CRNA (CRNA) News
Follow CRNA (CRNA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 18 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Circio Holding To Cancel Subsequent Offering
Circio Holding ASA OSL:CRNA
NEWS | Sep 23, 2026, 11:11 AM UTC
L
Circio Holding ASA (CRNA) Cancels Planned NOK 200M Subsequent Offering
Circio Holding ASA canceled its potential subsequent offering of up to 16,865,000 shares (~NOK 200M) after shares traded below the private placement price.Material DetailsContext by AI AnalystThis follows a NOK ~200M pri
EQUITY | Sep 23, 2026, 11:08 AM UTC
L
Circio Holding ASA Raises NOK 200M in Private Placement
Circio completed a private placement of 16,865,000 new shares at NOK 11.80, raising approx. NOK 200M. Settlement will use DVP with existing shares lent by shareholders under share lending agreements.Material DetailsConte
EQUITY | Sep 15, 2026, 06:50 AM UTC
L
Circio Holding ASA: Mandatory notification of trade (share lending in connection with private placement)
Oslo, Norway, 15 September 2026: Reference is made to the stock exchange announcement published by Circio Holding ASA ("Circio" or the "Company", OSE: CRNA) regarding the completion of a private placement (the "Private P
EQUITY | Sep 15, 2026, 06:50 AM UTC
L
Circio Holding Completes Private Placement Raising NOK 200 Mln In Gross Proceeds
Circio Holding ASA OSL:CRNA
NEWS | Sep 15, 2026, 06:36 AM UTC
L
Circio Holding ASA (OSL:CRNA) Trades Ex-Rights for Potential Subsequent Offering
Circio Holding ASA says its shares trade ex-rights from Sep 15, 2026 for a potential subsequent offering of up to 16.865M new shares.Material DetailsContext by AI AnalystThis is an early step in a potential capital raise
EQUITY | Sep 15, 2026, 06:36 AM UTC
L
Circio Holding ASA: Ex. right to participate in potential subsequent offering today
Reference is made to the stock exchange announcement made by Circio Holding ASA (the "Company") on 15 September 2026, regarding key information relating to a potential subsequent offering of up to 16,865,000 new shares i
EQUITY | Sep 15, 2026, 06:36 AM UTC
L
Circio Holding ASA (OSL:CRNA) Sets Terms for Potential NOK 200M Subsequent Offering
Circio Holding ASA outlined terms for a potential subsequent offering of up to 16,865,000 shares at NOK 11.80, matching its NOK 200M private placement. The offer is subject to a prospectus and market price/volume; the bo
EQUITY | Sep 15, 2026, 06:31 AM UTC
L
Circio Holding ASA: Key information relating to potential subsequent offering
NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DIS
NEWS | Sep 15, 2026, 06:30 AM UTC
L
Circio Holding ASA (OSL:CRNA) Raises NOK 200M in Private Placement at NOK 11.80
Circio Holding ASA completed a private placement of about NOK 200M, issuing 16,865,000 shares at NOK 11.80, a 9% discount to 14 Sep VWAP. Shares will be immediately tradable; settlement expected 17 Sep 2026.Material Deta
EQUITY | Sep 15, 2026, 06:24 AM UTC
L
Circio announces that it has completed a capital raise of approx. NOK 200 million towards its in vivo CAR-T program
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, ITS TERRITORIES OR POSSESSIONS, AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINIS
GEOPOLITICS | Sep 15, 2026, 06:24 AM UTC
M
CRNA platform advances drive up to 60x gene expression and NOK 620M funding
CRNA said its circVec technology achieved up to 60x gene expression in vivo. The company also raised NOK 620 million, securing funding through 2030, and expanded R&D plus 23 collaborations including major pharma.
EQUITY | Sep 01, 2026, 03:39 PM UTC
M
CRNA secures NOK 620 million funding, touts circVec gains
Circio Holding ASA said circVec delivered up to 60x improved gene expression in vivo, with next-gen targeting 200x, alongside NOK 620 million in funding to support R&D expansion and collaborations.
EQUITY | Sep 01, 2026, 12:00 PM UTC
M
CRNA raises NOK 620 million, funding through 2030
CRNA raised NOK 620 million to fund circVec R&D and business development through 2030. The company cites circVec technology advances, including up to 60x improved in-vivo gene expression.
EQUITY | Sep 01, 2026, 10:20 AM UTC
M
CRNA raises NOK 620 million for growth through 2030
CRNA said circVec technology advances showed up to 60x–200x improved gene expression in vivo and it has 23 collaborations underway. The company raised NOK 620 million to fund expanded gene and cell therapy programs throu
EQUITY | Sep 01, 2026, 09:33 AM UTC
L
CRNA says up to 60x gene expression boost; 20+ collaborations; NOK 620m raised
CRNA says it has an up to 60x gene expression boost, 20+ collaborations, and raised NOK 620m to secure growth through 2030.
EQUITY | Aug 31, 2026, 06:07 PM UTC
M
CRNA raises NOK 620 million; circVec platform validated
CRNA raised NOK 620 million, with its circVec platform validated and its financial position transformed.
EQUITY | Aug 31, 2026, 06:07 PM UTC
L
CRNA posts first-half progress in R&D, financing, business development
CRNA says its first-half report shows strong progress across R&D, financing and business development.
EQUITY | Aug 31, 2026, 06:05 PM UTC